[go: up one dir, main page]

CR9363A - Composiciones para la transmision transmucosa oral de la metformina - Google Patents

Composiciones para la transmision transmucosa oral de la metformina

Info

Publication number
CR9363A
CR9363A CR9363A CR9363A CR9363A CR 9363 A CR9363 A CR 9363A CR 9363 A CR9363 A CR 9363A CR 9363 A CR9363 A CR 9363A CR 9363 A CR9363 A CR 9363A
Authority
CR
Costa Rica
Prior art keywords
compositions
metformin
oral
transmuction
transmission
Prior art date
Application number
CR9363A
Other languages
English (en)
Inventor
Anna E Gluskin
Muhammad Waseem Tahir Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of CR9363A publication Critical patent/CR9363A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se relaciona con las composiciones farmaceuticas transmucosas orales que comprenden metformina o una sal farmaceuticamente aceptable de las mismas, metodos de utilizacion de las composiciones para tratar diversas enfermedades, incluyendo diabetes, metodos para preparar las composiciones, y las preparaciones a ser utilizadas para elaborar las composiciones.
CR9363A 2005-03-30 2007-09-04 Composiciones para la transmision transmucosa oral de la metformina CR9363A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30

Publications (1)

Publication Number Publication Date
CR9363A true CR9363A (es) 2008-02-12

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9363A CR9363A (es) 2005-03-30 2007-09-04 Composiciones para la transmision transmucosa oral de la metformina

Country Status (16)

Country Link
US (1) US20090069437A1 (es)
EP (1) EP1863465A4 (es)
JP (1) JP2008534523A (es)
AR (1) AR052960A1 (es)
AU (1) AU2006228949A1 (es)
BR (1) BRPI0611555A2 (es)
CA (1) CA2603450A1 (es)
CR (1) CR9363A (es)
IL (1) IL185931A0 (es)
MX (1) MX2007012047A (es)
NZ (1) NZ560990A (es)
PE (1) PE20061245A1 (es)
RU (2) RU2409357C2 (es)
UY (1) UY29445A1 (es)
WO (1) WO2006102752A1 (es)
ZA (1) ZA200708834B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
US20100286200A1 (en) * 2008-01-16 2010-11-11 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2445494A4 (en) * 2009-06-24 2012-12-12 Univ Koebenhavn TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
EP3278796A1 (en) 2011-10-28 2018-02-07 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
WO2020227344A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
WO1999055320A1 (en) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
NZ525559A (en) * 2000-11-03 2005-07-29 Andrx Labs Llc Controlled release metformin compositions for the reduction of serum glucose levels in human patients with NIDDM
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
EP1539144B1 (en) * 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
CA2543181A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin

Also Published As

Publication number Publication date
UY29445A1 (es) 2006-10-02
EP1863465A4 (en) 2010-12-15
PE20061245A1 (es) 2007-01-06
IL185931A0 (en) 2008-02-09
JP2008534523A (ja) 2008-08-28
US20090069437A1 (en) 2009-03-12
AR052960A1 (es) 2007-04-11
MX2007012047A (es) 2007-12-12
CA2603450A1 (en) 2006-10-05
BRPI0611555A2 (pt) 2010-09-21
RU2010139163A (ru) 2012-03-27
AU2006228949A1 (en) 2006-10-05
RU2007139886A (ru) 2009-05-10
RU2409357C2 (ru) 2011-01-20
NZ560990A (en) 2009-02-28
EP1863465A1 (en) 2007-12-12
ZA200708834B (en) 2008-11-26
WO2006102752A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CR9363A (es) Composiciones para la transmision transmucosa oral de la metformina
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
CL2007003685A1 (es) Compuestos derivados de indol con un anillo unido en las posiciones 4 y 5; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
PA8591701A1 (es) Derivados de pirrolopirimidina
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
DK1307227T3 (da) Farmaceutiske sammensætninger
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
ATE453642T1 (de) Substituierte phenylaminopyrimidine
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
AR109263A2 (es) Composición que comprende moxidectina
CR9079A (es) Nonadepsipeptidos acilados como derivados de lisobactina
NO20076405L (no) Anvendelse av 24-nor-UDCA
AR049876A1 (es) Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos
PA8547801A1 (es) Microcápsula para la protección frente al mal aliento
ATE455789T1 (de) Substituierte nonadepsipeptide
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)